March 27th 2023
Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have.
February 27th 2023
February 22nd 2023
Survey: What US and European retina specialists do and don’t know about biosimilarsFebruary 15th 2023
The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.
Poll: How familiar are you on the approval process for biosimilar drugs in comparison to new drug applications to the FDA?January 27th 2023
Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.
Ranibizumab biosimilar achieves similar results in patients with polypoidal choroidal vasculopathySeptember 27th 2022
Anti-VEGF biosimilars may offer a therapeutic alternative to the original biologic because they have the ability to lower the overall therapeutic cost in the management of varied chorioretinal disorders.
FDA approves Coherus’ interchangeable biosimilar for LucentisAugust 11th 2022
According to a news release, the U.S. Food and Drug Administration has approved Coherus’ ranibizumab-eqrn (Cimerli) as an interchangeable biosimilar for all five indications of Lucentis.